Document Detail

The effect of thymic substances on T circulating cells of patients treated for Hodgkin's disease.
MedLine Citation:
PMID:  3074627     Owner:  NLM     Status:  MEDLINE    
Forty-one patients with Hodgkin's disease staged as IA(4), IIA/B(4/6) IIIA/B(6/9) and IVA/B(3/9) who had had radiotherapy (subtotal nodal irradiation (STNI) or total nodal irradiation (TNI), or combined one (STNI/TNI plus chemotherapy MOPP or MOPP/ABVD) have been enrolled consequently and randomized to receive thymic hormone (17 patients) or pentapeptide treatment (14 patients) for 3-6 months at the end of the therapeutic regimens. In all patients severe immunodeficiency evaluated either as leukopenia (WBC less than 4000/mm3) or lymphocytopenia (lymphocytes less than 1500/mm3) or CD3 and CD2 cell reduction, or imbalance of helper/suppressor (H/S) ratio have been documented before starting thymic therapy. Different results by immunorestorative therapy have been registered according to the entity of immunodeficiency. In fact in the group of 15 patients with severe lymphopenia (lymphocytes less than 1000/mm3) either the thymic hormone or the synthetic drug produced a significant increase of all subsets examined: CD3-CD2-CD4-CD8 without or with minimal influence on H/S ratio, due to the increase of absolute lymphocytes count. In the remaining patients with mild or no lymphopenia the two drugs resulted ineffective on T cells. Comparing the overall group of patients who received thymic therapy with a control group of patients who did not, an advantage in terms of recruitment of T cell compartment has been observed in the former group when mean values are compared. According to the clinical impact of the immunotherapy with thymic substances on these patients, a significant decrease in incidence of herpes virus infection (HVI) has been observed in patients who had had thymic therapy compared with the incidence of HVI in the control group (18% versus 53.8%).(ABSTRACT TRUNCATED AT 250 WORDS)
T Chisesi; G Capnist; L Rancan; G Pellizzari; M Vespignani
Related Documents :
20026377 - Cd154 expression triggered by purine analogues in vitro: correlation with treatment res...
16837297 - Cell-mediated immunity in anorexia nervosa augmented lymphocyte transformation response...
1855177 - Lymphocyte abnormalities predicting a poor prognosis in hodgkin's disease. a long-term ...
4188267 - Dna polymerase activity as an index of lymphocyte stimulation: studies in down's syndrome.
6823427 - A new simplified technique for pediatric anorectal manometry.
1582517 - Carotid body tumours. a review of eight cases.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of biological regulators and homeostatic agents     Volume:  2     ISSN:  0393-974X     ISO Abbreviation:  J. Biol. Regul. Homeost. Agents     Publication Date:    1988 Oct-Dec
Date Detail:
Created Date:  1989-07-10     Completed Date:  1989-07-10     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8809253     Medline TA:  J Biol Regul Homeost Agents     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  193-8     Citation Subset:  IM; X    
Department of Hematology, S. Bortolo Hospital, Vicenza, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / adverse effects,  therapeutic use
Clinical Trials as Topic
Hodgkin Disease / drug therapy,  immunology*
Leukocyte Count / drug effects
Lymphopenia / chemically induced,  drug therapy
Peptide Fragments / pharmacology
Random Allocation
T-Lymphocytes / drug effects*
Thymopoietins / pharmacology
Thymus Extracts / pharmacology
Thymus Hormones / pharmacology*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Peptide Fragments; 0/Thymopoietins; 0/Thymus Extracts; 0/Thymus Hormones; 0/thymostimulin; 69558-55-0/Thymopentin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Evidence that an L-fucose-containing component in the beta-cell plasma membrane is involved in the r...
Next Document:  Enzymatic mechanisms of resistance to alkylating agents in tumor cells and normal tissues.